Transportador

Compound 12f, a DMT1 blocker, inhibits DMT1 with a 0.83 IC50, potentially blocking intestinal iron absorption.

Promazine hydrochloride, a phenothiazine less potent than chlorpromazine, treats disturbed behavior and nausea.

Brilliant Yellow (Direct Yellow 4) is a potent and selective VGLUT inhibitor, a dye that is photodegradable.

"SLC26A3-IN-1 inhibits SLC26A3, an anion transporter linked to diarrhea, with 340 nM IC50."

GPNA hydrochloride inhibits Gln transporter ASCT2, induces apoptosis in A549 cells, blocks SNAT1/2/4/5 & LAT1/2 transporters, and is a GGT substrate.

LDN-212320 (OSU-0212320) is a glutamate transporter EAAT2 activator. It also enhances EAAT2 levels by > 6 fold at concentrations < 5 μM after 24 h.

Cinromide (trans-3-Bromo-N-ethylcinnamamide) is used as a novel anticonvulsant agent.

D-Carnitine hydrochloride ((S)-Carnitine Hydrochloride), a constituent of striated muscle and liver, is used in the treatment of hyperlipoproteinemias.

Membrane proteins are a class of proteins widely found in biological cell membranes, playing essential roles in the structure and function of cells. Based on their location and function, membrane proteins can be classified into three main categories: peripheral membrane proteins, integral membrane proteins, and lipid-anchored proteins. Membrane proteins encompass a variety of functional proteins, including glycoproteins, carrier proteins, and enzymes. They are often linked to carbohydrate molecules, which can transmit signals into the cell by undergoing structural changes, participating in signal transduction processes. Membrane proteins perform a range of critical functions, including substance transport, signal transduction, cell recognition, and energy conversion. In drug development, membrane proteins, especially G protein-coupled receptors (GPCRs), ion channels, and transporters, are of particular interest. Many diseases are related to the malfunction of specific membrane proteins. Therefore, drugs designed to target these proteins can regulate their activity, aiming to treat diseases. TargetMol has collected 6422 compounds that target membrane proteins, which can be used for membrane protein-related scientific research and drug screening, suitable for high-throughput and high-content screening.

MSNBA inhibits GLUT5 fructose uptake (KI: 3.2±0.4 μM) in MCF7 cells, serving as a potent GLUT5 probe.

Rapaglutin A is a glucose transporter (GLUT) inhibitor. It acts as a pan-GLUT inhibitor for the class I isomers GLUT1, GLUT3, and GLUT4, with an IC50 of 12 nM. Additionally, Rapaglutin A inhibits the proliferation of A549 cells.

EAAT2 activator2 (Compound 4(SF-2)) is a brain-penetrant modulator of excitatory amino acid transporter 2 (EAAT2) with a Ki of 28.7 nM. This compound enhances EAAT2-mediated glutamate uptake and improves synaptic glutamate clearance. EAAT2 activator2 holds potential for research into neurodegenerative diseases, such as amyotrophic lateral sclerosis and Alzheimer's disease.

GLUT inhibitor-1: oral, targets GLUT1/3 (IC50: 242/179 nM), for cancer/autoimmune research.

WZB117-PPG is an inhibitor of glucose transporter 1 (GLUT1) with anticancer properties. Under visible light irradiation, this compound demonstrates significant photolytic efficiency and cytotoxicity toward cancer cells.

SW157765 is a glucose transporter GLUT8 inhibitor that inhibits the uptake of fluorescent 2-deoxyglucose (2DG) in SW157765-sensitized cells.

UCPH-101 is an inhibitor of excitatory amino acid transporter subtype 1 (EAAT1) with an IC50 of 0.66 μM.

KL-11743 blocks glucose metabolism, collapses NADH, and increases aspartate, shifting cells to oxidative phosphorylation.

Indican (Indoxyl-β-D-glucoside) is a natural protective compound that is used to protect the liver.

BAY-876 is a selective and orally GLUT1 inhibitor. BAY-876 inhibits glycolytic metabolism and exhibits antitumor activity. Cost-effective and quality-assured.